Featured Press Releases

Qualia NAD+ Shown In Preliminary Clinical Study To Increase NAD+ By 85%

Qualia NAD+ Shown In Preliminary Clinical Study To Increase NAD+ By 85%

Lutris Pharma secures $30 million in financing to advance the development of a biopharmaceutical aimed at improving the effectiveness of anti-cancer drugs

Lutris Pharma secures $30 million in financing to advance the development of a biopharmaceutical aimed at improving the effectiveness of anti-cancer drugs

  • 23 Jan 2025

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer...

Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

Bruker Introduces nVista 2P Miniature Microscope

Bruker Introduces nVista 2P Miniature Microscope

Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

  • Virax BioLabs Group Limited
  • 16 Jul 2026
Children

Children's Hospital of Philadelphia Initiative Substantially Increases Naloxone Co-Prescribing When Prescribing Outpatient Opioids

  • Children's Hospital of Philadelphia
  • 16 Jul 2026
Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

  • Hologic, Inc.
  • 14 Jul 2026
Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

  • Merck
  • 14 Jul 2026
BioMarin

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

  • BioMarin Pharmaceutical Inc.
  • 13 Jul 2026
FDA Approves Expanded Indication for Octapharma USA

FDA Approves Expanded Indication for Octapharma USA's wilate® for Prophylaxis of von Willebrand Disease in Children Younger Than 6 Years

  • Octapharma
  • 10 Jul 2026
The Digital Pharma Advances Conference 2026

Most Popular
July   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.